ETFMG Treatments, Testing and Advancements ETF
|
|
|
|
|
|
|
Schedule of Investments
|
|
|
|
|
|
|
June 30, 2023 (Unaudited)
|
|
|
|
|
|
|
|
|
Shares
|
|
|
Value
|
|
COMMON STOCKS - 99.5%
|
|
|
|
|
|
|
Canada - 4.4%
|
|
|
|
|
|
|
Biotechnology - 1.0% (d)
|
|
|
|
|
|
|
Arbutus Biopharma Corp. (a)
|
|
|
53,155
|
|
|
$
|
122,257
|
|
VBI Vaccines, Inc. (a)
|
|
|
10
|
|
|
|
33
|
|
XBiotech, Inc. (a)
|
|
|
9,739
|
|
|
|
57,850
|
|
Total Biotechnology
|
|
|
|
|
|
|
180,140
|
|
Life Sciences Tools & Services - 3.4%
|
|
|
|
|
|
|
|
|
AbCellera Biologics, Inc. (a)(b)
|
|
|
92,379
|
|
|
|
596,768
|
|
Total Canada
|
|
|
|
|
|
|
776,908
|
|
|
|
|
|
|
|
|
|
|
Cayman Islands - 3.3%
|
|
|
|
|
|
|
|
|
Biotechnology - 3.3% (d)
|
|
|
|
|
|
|
|
|
Zai Lab, Ltd. - ADR (a)(b)
|
|
|
20,923
|
|
|
|
580,195
|
|
|
|
|
|
|
|
|
|
|
France - 0.8%
|
|
|
|
|
|
|
|
|
Pharmaceuticals - 0.8%
|
|
|
|
|
|
|
|
|
Sanofi - ADR
|
|
|
2,631
|
|
|
|
141,811
|
|
|
|
|
|
|
|
|
|
|
Germany - 6.1%
|
|
|
|
|
|
|
|
|
Biotechnology - 6.1% (d)
|
|
|
|
|
|
|
|
|
BioNTech SE - ADR (a)
|
|
|
9,947
|
|
|
|
1,073,580
|
|
|
|
|
|
|
|
|
|
|
Japan - 0.7%
|
|
|
|
|
|
|
|
|
Pharmaceuticals - 0.7%
|
|
|
|
|
|
|
|
|
Takeda Pharmaceutical Co., Ltd. - ADR (b)
|
|
|
8,356
|
|
|
|
131,273
|
|
|
|
|
|
|
|
|
|
|
Netherlands - 4.7%
|
|
|
|
|
|
|
|
|
Biotechnology - 4.7% (d)
|
|
|
|
|
|
|
|
|
CureVac NV (a)(b)
|
|
|
71,619
|
|
|
|
746,270
|
|
InflaRx NV (a)
|
|
|
17,314
|
|
|
|
77,220
|
|
Total Biotechnology
|
|
|
|
|
|
|
823,490
|
|
|
|
|
|
|
|
|
|
|
United Kingdom - 5.8%
|
|
|
|
|
|
|
|
|
Biotechnology - 4.3% (d)
|
|
|
|
|
|
|
|
|
Immunocore Holdings PLC - ADR (a)(b)
|
|
|
12,542
|
|
|
|
752,018
|
|
Pharmaceuticals - 1.5%
|
|
|
|
|
|
|
|
|
AstraZeneca PLC - ADR
|
|
|
1,823
|
|
|
|
130,472
|
|
GSK PLC - ADR
|
|
|
3,928
|
|
|
|
139,994
|
|
Total Pharmaceuticals
|
|
|
|
|
|
|
270,466
|
|
Total United Kingdom
|
|
|
|
|
|
|
1,022,484
|
|
|
|
|
|
|
|
|
|
|
United States - 73.7%
|
|
|
|
|
|
|
|
|
Biotechnology - 37.8% (d)
|
|
|
|
|
|
|
|
|
AbbVie, Inc.
|
|
|
995
|
|
|
|
134,056
|
|
Alnylam Pharmaceuticals, Inc. (a)
|
|
|
5,489
|
|
|
|
1,042,581
|
|
Altimmune, Inc. (a)
|
|
|
15,771
|
|
|
|
55,672
|
|
Arcturus Therapeutics Holdings, Inc. (a)(b)
|
|
|
8,499
|
|
|
|
243,751
|
|
BioCryst Pharmaceuticals, Inc. (a)(b)
|
|
|
60,450
|
|
|
|
425,568
|
|
CEL-SCI Corp. (a)(b)
|
|
|
14,307
|
|
|
|
34,480
|
|
Chimerix, Inc. (a)
|
|
|
28,343
|
|
|
|
34,295
|
|
Cue Biopharma, Inc. (a)
|
|
|
13,815
|
|
|
|
50,425
|
|
Dynavax Technologies Corp. (a)(b)
|
|
|
41,110
|
|
|
|
531,141
|
|
Emergent BioSolutions, Inc. (a)
|
|
|
16,141
|
|
|
|
118,636
|
|
Enanta Pharmaceuticals, Inc. (a)
|
|
|
6,737
|
|
|
|
144,172
|
|
Gilead Sciences, Inc.
|
|
|
1,742
|
|
|
|
134,256
|
|
Gritstone bio, Inc. (a)
|
|
|
28,448
|
|
|
|
55,474
|
|
HilleVax, Inc. (a)
|
|
|
12,542
|
|
|
|
215,597
|
|
Icosavax, Inc. (a)
|
|
|
15,907
|
|
|
|
157,957
|
|
ImmunityBio, Inc. (a)(b)
|
|
|
139,494
|
|
|
|
387,793
|
|
Inovio Pharmaceuticals, Inc. (a)(b)
|
|
|
84,065
|
|
|
|
37,535
|
|
Invivyd, Inc. (a)
|
|
|
35,029
|
|
|
|
36,780
|
|
Moderna, Inc. (a)
|
|
|
8,059
|
|
|
|
979,169
|
|
Novavax, Inc. (a)(b)
|
|
|
27,613
|
|
|
|
205,165
|
|
Ocugen, Inc. (a)(b)
|
|
|
83,484
|
|
|
|
45,340
|
|
Regeneron Pharmaceuticals, Inc. (a)
|
|
|
182
|
|
|
|
130,774
|
|
Vaxart, Inc. (a)(b)
|
|
|
43,385
|
|
|
|
31,671
|
|
Vaxcyte, Inc. (a)
|
|
|
13,727
|
|
|
|
685,526
|
|
Vaxxinity, Inc. - Class A (a)(b)
|
|
|
40,487
|
|
|
|
102,027
|
|
Vir Biotechnology, Inc. (a)(b)
|
|
|
25,677
|
|
|
|
629,857
|
|
Total Biotechnology
|
|
|
|
|
|
|
6,649,698
|
|
Health Care Equipment & Supplies - 6.1%
|
|
|
|
|
|
|
|
|
Abbott Laboratories
|
|
|
1,291
|
|
|
|
140,745
|
|
Cue Health, Inc. (a)
|
|
|
48,511
|
|
|
|
17,901
|
|
Hologic, Inc. (a)
|
|
|
1,678
|
|
|
|
135,868
|
|
OraSure Technologies, Inc. (a)(b)
|
|
|
23,441
|
|
|
|
117,439
|
|
QuidelOrtho Corp. (a)(b)
|
|
|
8,061
|
|
|
|
667,934
|
|
Total Health Care Equipment & Supplies
|
|
|
|
|
|
|
1,079,887
|
|
Health Care Providers & Services - 18.1%
|
|
|
|
|
|
|
|
|
Enzo Biochem, Inc. (a)
|
|
|
15,890
|
|
|
|
29,238
|
|
Fulgent Genetics, Inc. (a)
|
|
|
9,503
|
|
|
|
351,896
|
|
Laboratory Corp. of America Holdings
|
|
|
4,875
|
|
|
|
1,176,483
|
|
OPKO Health, Inc. (a)(b)
|
|
|
247,278
|
|
|
|
536,593
|
|
Quest Diagnostics, Inc.
|
|
|
7,726
|
|
|
|
1,085,967
|
|
Total Health Care Providers & Services
|
|
|
|
|
|
|
3,180,177
|
|
Life Sciences Tools & Services - 5.8%
|
|
|
|
|
|
|
|
|
Adaptive Biotechnologies Corp. (a)
|
|
|
46,173
|
|
|
|
309,821
|
|
Bio-Rad Laboratories, Inc. - Class A (a)
|
|
|
1,859
|
|
|
|
704,784
|
|
Total Life Sciences Tools & Services
|
|
|
|
|
|
|
1,014,605
|
|
Pharmaceuticals - 6.0%
|
|
|
|
|
|
|
|
|
AN2 Therapeutics, Inc. (a)(b)
|
|
|
6,215
|
|
|
|
52,828
|
|
Atea Pharmaceuticals, Inc. (a)
|
|
|
26,684
|
|
|
|
99,798
|
|
CorMedix, Inc. (a)
|
|
|
14,519
|
|
|
|
57,568
|
|
Eli Lilly and Co.
|
|
|
304
|
|
|
|
142,569
|
|
Johnson & Johnson
|
|
|
859
|
|
|
|
142,181
|
|
Merck & Co, Inc.
|
|
|
1,197
|
|
|
|
138,122
|
|
Paratek Pharmaceuticals, Inc. (a)
|
|
|
18,328
|
|
|
|
40,505
|
|
Pfizer, Inc.
|
|
|
3,492
|
|
|
|
128,087
|
|
Scilex Holding Co. (a)
|
|
|
23,669
|
|
|
|
131,834
|
|
SIGA Technologies, Inc.
|
|
|
22,802
|
|
|
|
115,150
|
|
Total Pharmaceuticals
|
|
|
|
|
|
|
1,048,642
|
|
Total United States
|
|
|
|
|
|
|
12,973,009
|
|
TOTAL COMMON STOCKS (Cost $29,882,764)
|
|
|
|
|
|
|
17,522,750
|
|
|
|
|
|
|
|
|
|
|
INVESTMENTS PURCHASED WITH PROCEEDS FROM SECURITIES LENDING COLLATERAL - 32.8%
|
|
|
|
|
|
|
|
|
ETFMG Sit Ultra Short ETF (e)
|
|
|
25,000
|
|
|
|
1,212,250
|
|
Mount Vernon Liquid Assets Portfolio, LLC, 5.22% (c)
|
|
|
4,561,148
|
|
|
|
4,561,148
|
|
TOTAL INVESTMENTS PURCHASED WITH PROCEEDS FROM SECURITIES LENDING COLLATERAL (Cost $5,805,123)
|
|
|
|
|
|
|
5,773,398
|
|
|
|
|
|
|
|
|
|
|
SHORT-TERM INVESTMENTS - 0.6%
|
|
|
|
|
|
|
|
|
Money Market Funds - 0.6%
|
|
|
|
|
|
|
|
|
First American Government Obligations Fund - Class X, 5.01% (c)
|
|
|
96,824
|
|
|
|
96,824
|
|
TOTAL SHORT-TERM INVESTMENTS (Cost $96,824)
|
|
|
|
|
|
|
96,824
|
|
|
|
|
|
|
|
|
|
|
Total Investments (Cost $35,784,711) - 132.9%
|
|
|
|
|
|
|
23,392,972
|
|
Liabilities in Excess of Other Assets - (32.9)%
|
|
|
|
|
|
|
(5,785,253
|
)
|
TOTAL NET ASSETS - 100.0%
|
|
|
|
|
|
$
|
17,607,719
|
|
Percentages are stated as a percent of net assets.
|
|
|
ADR
|
American Depositary Receipt
|
|
|
|
PLC
|
Public Limited Company
|
|
|
|
(a)
|
Non-income producing security.
|
|
|
|
(b)
|
All or a portion of this security was out on loan at June 30, 2023.
|
|
|
|
(c)
|
The rate shown is the annualized seven-day yield at period end.
|
|
|
|
(d)
|
As of June 30, 2023 the Fund had a significant portion of its assets in the Biotechnology Industry.
|
|
|
|
(e)
|
Affiliated security. A schedule of the Fund’s investments in securities of affiliated issuers held during the period ended June 30, 2023 is set
forth below.
|
|
|
|
|
|
The Global Industry Classification Standard (GICS®) was developed by and/or is the exclusive property of MSCI, Inc. and Standard &
Poor’s Financial Services LLC (“S&P”). GICS is a service mark of MSCI and S&P and has been licensed for use by U.S. Bancorp Fund Services, LLC, doing business as U.S. Bank Global Fund Services (“Fund Services”).
|
|
|
|
|
|
The accompanying notes are an integral part of these financial statements.
|